The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States
Abstract
OBJECTIVE: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on costs and utility. METHODS: Data on demographics, disease information, resource utilization (including work capacity), and utility were collected directly from patients in a cross-sectional postal survey. Patients were selected randomly among participants in the North American Committee on Multiple Sclerosis Patient Registry (NARCOMS) receiving DMDs. Mean annual costs per patient (2004 USD) and mean utilities for the sample and for different levels of functional disability are estimated from the societal perspective. RESULTS: The target answer rate of 50% was reached and 1,909 patients were included in the analysis. The mean age was 49 years and time since diagnosis was 13 years. A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease. A total of 28.8% of patients indicated to have experienced a relapse during the past 3 months. Total average costs are estimated at 47,215 dollars per patient and year. Of these, 53% were for direct medical and non-medical costs, 37% for production losses, and 10% for informal care. Mean utility in the sample was 0.698. CONCLUSIONS: Consistent with other studies, costs and utilities were significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model
Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005) · Medical Care · doi:10.1097/00005650-200503000-00003 · Cited by 1,274
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
A social tariff for EuroQol: results from a UK general population surveyPreprint
Dolan, P., Gudex, C. M., Kind, P., & Williams, A. (1995) · RePEc: Research Papers in Economics · Cited by 611
Disease Steps in multiple sclerosis: A simple approach to evaluate disease progression
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1995) · Neurology · doi:10.1212/wnl.45.2.251 · Cited by 551
A comprehensive assessment of the cost of multiple sclerosis in the United States
Whetten-Goldstein, K., Sloan, F. A., Goldstein, L. B., & Kulas, E. D. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400504 · Cited by 230
Valuations of EQ-5D Health States: Are the United States and United Kingdom Different?
Johnson, J. A., Luo, N., Shaw, J. W., Kind, P., & Coons, S. J. (2005) · Medical Care · doi:10.1097/00005650-200503000-00004 · Cited by 222
Costs, quality of life and disease severity in multiple sclerosis: a cross‐sectional study in Sweden
Henriksson, F., Fredrikson, S., Masterman, T., & Jönsson, B. (2001) · European Journal of Neurology · doi:10.1046/j.1468-1331.2001.00169.x · Cited by 184
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom
Murphy, N., Confavreux, C., Haas, J., Konig, N., Roullet, E., Sailer, M., Swash, M., Young, C., & J-L, M. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.460 · Cited by 119
Cited by
Learmonth, Y. C., Motl, R. W., Sandroff, B. M., Pula, J. H., & Cadavid, D. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-37 · Cited by 773
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Self-citationThe burden of neurological disease in theUnitedStates: A summary report and call to action
Gooch, C. L., Pracht, E., & Borenstein, A. R. (2017) · Annals of Neurology · doi:10.1002/ana.24897 · Cited by 388
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
Marrie, R. A., Yu, N., Blanchard, J., Leung, S., & Elliott, L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cf6ec0 · Cited by 307
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung, D. M., Bourdette, D. N., Ahmed, S. M., & Whitham, R. H. (2015) · Neurology · doi:10.1212/wnl.0000000000001608 · Cited by 261
Metadata
- Authors
- Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O.
- Venue
- Neurology
- Published
- 2006-06-13
- Volume
- 66
- Issue
- 11
- Pages
- 1696-1702
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2131902490
- Cited by
- 286
- References
- 17
- FWCI
- 42.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. https://app.cochat.ai/papers/10.1212/01.wnl.0000218309.01322.5c
- The paper
- Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O. (2006). Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology. https://doi.org/10.1212/01.wnl.0000218309.01322.5c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.